VOYAGER THERAPEUTICS INC's ticker is VYGR and the CUSIP is 92915B106. A total of 125 filers reported holding VOYAGER THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.17 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,494,735 | -31.8% | 192,869 | +0.8% | 0.00% | – |
Q2 2023 | $2,191,686 | +188.6% | 191,414 | +94.4% | 0.00% | – |
Q1 2023 | $759,340 | +26.4% | 98,488 | 0.0% | 0.00% | – |
Q4 2022 | $600,775 | +2.9% | 98,488 | -0.2% | 0.00% | – |
Q3 2022 | $584,000 | 0.0% | 98,717 | 0.0% | 0.00% | – |
Q2 2022 | $584,000 | +79.7% | 98,717 | +131.7% | 0.00% | – |
Q1 2022 | $325,000 | +182.6% | 42,601 | 0.0% | 0.00% | – |
Q4 2021 | $115,000 | -50.4% | 42,601 | -51.8% | 0.00% | – |
Q3 2021 | $232,000 | -38.5% | 88,387 | -3.1% | 0.00% | – |
Q2 2021 | $377,000 | -54.6% | 91,256 | -48.3% | 0.00% | – |
Q1 2021 | $831,000 | -34.8% | 176,590 | -0.9% | 0.00% | – |
Q4 2020 | $1,274,000 | -89.5% | 178,227 | -84.4% | 0.00% | -100.0% |
Q3 2020 | $12,188,000 | -14.0% | 1,142,226 | +1.8% | 0.00% | -25.0% |
Q2 2020 | $14,165,000 | +72.4% | 1,122,435 | +25.0% | 0.00% | +33.3% |
Q1 2020 | $8,217,000 | +5.7% | 898,189 | +61.1% | 0.00% | +50.0% |
Q4 2019 | $7,777,000 | +351.6% | 557,539 | +457.2% | 0.00% | – |
Q3 2019 | $1,722,000 | -36.7% | 100,066 | +0.2% | 0.00% | -100.0% |
Q2 2019 | $2,719,000 | +58.9% | 99,860 | +11.7% | 0.00% | – |
Q1 2019 | $1,711,000 | +105.9% | 89,398 | +1.1% | 0.00% | – |
Q4 2018 | $831,000 | -48.3% | 88,459 | +4.2% | 0.00% | – |
Q3 2018 | $1,607,000 | -1.8% | 84,916 | +1.4% | 0.00% | – |
Q2 2018 | $1,636,000 | +4.2% | 83,710 | +0.2% | 0.00% | – |
Q1 2018 | $1,570,000 | +21.6% | 83,539 | +7.5% | 0.00% | – |
Q4 2017 | $1,291,000 | +1.3% | 77,746 | +25.7% | 0.00% | – |
Q3 2017 | $1,274,000 | +167.1% | 61,858 | +16.2% | 0.00% | – |
Q2 2017 | $477,000 | -18.0% | 53,225 | +20.9% | 0.00% | – |
Q1 2017 | $582,000 | +20.0% | 44,018 | +15.6% | 0.00% | – |
Q4 2016 | $485,000 | +20.9% | 38,066 | +14.1% | 0.00% | – |
Q3 2016 | $401,000 | +9.9% | 33,365 | +0.3% | 0.00% | – |
Q2 2016 | $365,000 | +78.0% | 33,275 | +41.8% | 0.00% | – |
Q1 2016 | $205,000 | -33.2% | 23,472 | +67.8% | 0.00% | – |
Q4 2015 | $307,000 | – | 13,991 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP III, LLC | 6,391,176 | $109,992,000 | 62.32% |
Foresite Capital Management IV, LLC | 830,565 | $14,294,000 | 4.62% |
Casdin Capital, LLC | 1,128,075 | $19,414,171,000 | 2.01% |
ARMISTICE CAPITAL, LLC | 1,096,000 | $18,862,000 | 1.25% |
Bellevue Group AG | 2,704,683 | $46,548,000 | 0.87% |
PFM Health Sciences, LP | 1,231,954 | $21,202,000 | 0.63% |
Boxer Capital, LLC | 500,000 | $8,605,000 | 0.62% |
Aevitas Wealth Management, Inc. | 23,150 | $398,000 | 0.40% |
361 CAPITAL LLC | 120,143 | $2,068,000 | 0.38% |
Birchview Capital, LP | 30,000 | $516,000 | 0.34% |